探索使用结构差异化抑制剂治疗抑郁症的神经素-1受体对抗性
Hyeijung Yoo1, Kyung-Jun Boo2, Lan Phuong Nguyen3
1Department of Anatomy, College of Medicine, Korea University, Seoul, Republic of Korea.
Experimental & molecular medicine
|November 27, 2025
概括
结构上多样化的神经素-1受体 (NK1R) 抗剂,与以前的候选药物不同,在治疗严重抑郁症方面表现有前途. 在临床前模型中,新型NK1R抗剂有效地减少了类似抑郁症的行为.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 计算化学的计算化学
背景情况:
- 神经-1受体 (NK1R) 是主要抑郁障碍 (MDD) 的潜在目标,因为它在压力和神经炎症中的作用.
- 以前的NK1R抗剂产生了不一致的临床结果,可能是由于它们的化学结构 (3,5-bis-trifluoromethylphenyl部分).
- 结构上不同的NK1R抗剂的治疗潜力仍然未被探索.
研究的目的:
- 识别和评估缺乏3,5-bis-trifluoromethylphenyl组的新型NK1R抗剂.
- 在临床前模型中评估这些结构多样化的化合物的抗抑郁药物潜力.
- 通过使用计算模拟来研究一个有前途的新型对手的结合模式.
主要方法:
- 使用计算方法来识别NK1R对手.
- 抑郁症的临床前模型被用于评估化合物疗效.
- 进行了分子对接和分子动力学模拟,以分析结合相互作用.
主要成果:
- 几种新的NK1R抗剂在减少类似抑郁的行为方面表现出有效性.
- 化合物#15在临床前模型中表现出最显著的抗抑郁作用.
- 分子模拟揭示了化合物#15的独特结合模式,包括结和π-π堆叠.
结论:
- 结构多样化的NK1R抗剂有可能调节MDD中的行为和神经炎症.
- 新的化学支架可以克服与以前NK1R抗剂相关的局限性.
- 需要进行进一步的研究,以确定这些发现对重大抑郁症治疗的临床相关性.
更多相关视频
07:58Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression
Published on: February 24, 2023
798
10:20Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b
Published on: November 11, 2016
8.9K
相关概念视频
01:23Antidepressant Drugs: MAOIs and Other Agents
774
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
774
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
524
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
524
01:25Antidepressant Drugs: Overview
1.3K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
1.3K
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
1.3K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
1.3K
01:21Drugs Affecting Neurotransmitter Release or Uptake
1.5K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.5K
01:21G-protein Coupled Receptors
131.3K
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
131.3K